Cornerstone Capital Management Holdings’s Ligand Pharmaceuticals LGND Stock Holding History

Cornerstone Capital Management Holdings’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	$1.29M	Buy	15,089 +321	+2%	+$27.8K	0.01%	857
2017 Q3	$1.25M	Buy	14,768 +320	+2%	+$25.3K	0.01%	881
2017 Q2	$1.09M	Sell	14,448 -1,103	-7%	-$77.2K	0.01%	887
2017 Q1	$1.03M	Buy	15,551 +10,147	+188%	+$668K	0.01%	924
2016 Q4	$341K	Sell	5,404 -801	-13%	-$50.5K	﹤0.01%	1138
2016 Q3	$394K	Buy	6,205 +2,244	+57%	+$165K	﹤0.01%	1108
2016 Q2	$295K	Buy	3,961 +1,122	+40%	+$83.3K	﹤0.01%	1132
2016 Q1	$190K	Sell	2,839 -962	-25%	-$58.5K	﹤0.01%	1214
2015 Q4	$257K	Buy	3,801 +1,717	+82%	+$106K	﹤0.01%	1164
2015 Q3	$111K	Hold	2,084	–	–	﹤0.01%	1321
2015 Q2	$131K	Buy	2,084 +1,122	+117%	+$61.2K	﹤0.01%	1269
2015 Q1	$46K	Hold	962	–	–	﹤0.01%	1313
2014 Q4	$32K	Buy	962 +321	+50%	+$10.4K	﹤0.01%	1220
2014 Q3	$19K	Buy	+641	New	+$21.3K	﹤0.01%	1241

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DMK

David M. Knott $275M AUM 59.23% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Cornerstone Capital Management Holdings's LGND Position: Q4 2017 in Review

Cornerstone Capital Management Holdings increased its Ligand Pharmaceuticals (LGND) stake by 2.2% in Q4 2017, buying an estimated $27.8K and bringing the position to 15,089 shares worth $1.29M. The position accounts for 0.01% of the portfolio, ranked #857.

Cornerstone Capital Management Holdings first reported a position in LGND in Q3 2014 and has held it in 14 quarters since. 298 funds tracked by Wall St. Rank hold LGND as of Q4 2017.

Cornerstone Capital Management Holdings held 15,089 shares of Ligand Pharmaceuticals worth $1.29M as of Q4 2017.
Cornerstone Capital Management Holdings bought 321 Ligand Pharmaceuticals shares in Q4 2017, an estimated $27.8K.
Ligand Pharmaceuticals made up 0.01% of Cornerstone Capital Management Holdings's portfolio in Q4 2017, its #857 holding.
Cornerstone Capital Management Holdings first reported a position in Ligand Pharmaceuticals in Q3 2014 and has held it in 14 quarters since.
298 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2017.

Based on Cornerstone Capital Management Holdings's 13F filing for Q4 2017, filed 14 Feb 2018.